Trends in Prostate-Specific Antigen Screening and Prostate Cancer Interventions 3 Years After the U.S. Preventive Services Task Force Recommendation
Authors: Mei-Sing Ong, Kenneth D. Mandl
Journal: Annals of Internal Medicine (2017)

Letters21 March 2017Trends in Prostate-Specific Antigen Screening and Prostate Cancer Interventions 3 Years After the U.S. Preventive Services Task Force RecommendationMei-Sing Ong, PhD and Kenneth D. Mandl, MD, MPHMei-Sing Ong, PhDFrom Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.Search for more papers by this author and Kenneth D. Mandl, MD, MPHFrom Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0422 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: In 2012, the U.S. Preventive Services Task Force (USPSTF) advised against routine prostate-specific antigen (PSA) screening for prostate cancer in asymptomatic men (1). Studies reported a substantial decline in the prevalence of PSA screening 1 year after the recommendation was published (2–5). We sought to measure whether this change persisted and whether trends in prostate cancer treatment have changed.Methods: We examined routine use of PSA screening and prostate cancer treatment before and after publication of the 2012 USPSTF recommendation (between 2009 and 2015) using claims from Aetna, a commercial health insurer in the United States. The Boston Children's ...References1. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-34. [PMID: 22801674]. doi:10.7326/0003-4819-157-2-201207170-00459 LinkGoogle Scholar2. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314:2054-61. [PMID: 26575061] doi:10.1001/jama.2015.14905 CrossrefMedlineGoogle Scholar3. Sammon JD, Abdollah F, Choueiri TK, Kantoff PW, Nguyen PL, Menon M, et al. Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA. 2015;314:2077-9. [PMID: 26575066] doi:10.1001/jama.2015.7273 CrossrefMedlineGoogle Scholar4. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol. 2015;33:2416-23. [PMID: 26056181] doi:10.1200/JCO.2015.61.6532 CrossrefMedlineGoogle Scholar5. Li J, Berkowitz Z, Hall IJ. Decrease in prostate cancer testing following the US Preventive Services Task Force (USPSTF) recommendations. J Am Board Fam Med. 2015;28:491-3. [PMID: 26152440] doi:10.3122/jabfm.2015.04.150062 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.Disclaimer: The funding bodies played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. All authors made substantial contributions to the conception, design and interpretation of data, and writing of the manuscript and gave final approval of the version to be published. Dr. Ong had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Grant Support: By Aetna. Dr. Ong is supported by a grant from the National Health and Medical Research Council, Australia (APP1052871), and the National Institutes of Health (T15LM007092).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0422. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUse of the prostate‐specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventionsTemporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancerTime trends in prostate cancer screening in Swiss primary care (2010 to 2017) – A retrospective studyExnovation of Low Value Care: A Decade of Prostate-Specific Antigen Screening PracticesImpact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare BeneficiariesContemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases 21 March 2017Volume 166, Issue 6Page: 451-452KeywordsAntigensBiopsyCancer screeningDisclosureHealth careHealth surveysMortalityProstate cancerProstatectomyRadiation therapy ePublished: 21 March 2017 Issue Published: 21 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...